Literature DB >> 24634143

The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations.

Kyu Sang Joeng1, Yi-Chien Lee1, Ming-Ming Jiang2, Terry K Bertin1, Yuqing Chen2, Annie M Abraham3, Hao Ding4, Xiaohong Bi4, Catherine G Ambrose3, Brendan H Lee5.   

Abstract

Osteogenesis imperfecta (OI) is a heritable disorder of connective tissue characterized by bone fragility and low bone mass. Recently, our group and others reported that WNT1 recessive mutations cause OI, whereas WNT1 heterozygous mutations cause early onset osteoporosis. These findings support the hypothesis that WNT1 is an important WNT ligand regulating bone formation and bone homeostasis. While these studies provided strong human genetic and in vitro functional data, an in vivo animal model to study the mechanism of WNT1 function in bone is lacking. Here, we show that Swaying (Wnt1(sw/sw)) mice previously reported to carry a spontaneous mutation in Wnt1 share major features of OI including propensity to fractures and severe osteopenia. In addition, biomechanical and biochemical analyses showed that Wnt1(sw/sw) mice exhibit reduced bone strength with altered levels of mineral and collagen in the bone matrix that is also distinct from the type I collagen-related form of OI. Further histomorphometric analyses and gene expression studies demonstrate that the bone phenotype is associated with defects in osteoblast activity and function. Our study thus provides in vivo evidence that WNT1 mutations contribute to bone fragility in OI patients and demonstrates that the Wnt1(sw/sw) mouse is a murine model of OI caused by WNT1 mutations.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634143      PMCID: PMC4082367          DOI: 10.1093/hmg/ddu117

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

2.  Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta.

Authors:  M L Chu; C J Williams; G Pepe; J L Hirsch; D J Prockop; F Ramirez
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

3.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Lynn M Boyden; Junhao Mao; Joseph Belsky; Lyle Mitzner; Anita Farhi; Mary A Mitnick; Dianqing Wu; Karl Insogna; Richard P Lifton
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

Review 4.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

5.  Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy.

Authors:  Xiaohong Bi; Julie A Sterling; Alyssa R Merkel; Daniel S Perrien; Jeffry S Nyman; Anita Mahadevan-Jansen
Journal:  Bone       Date:  2013-07-15       Impact factor: 4.398

6.  High bone mass in mice expressing a mutant LRP5 gene.

Authors:  Philip Babij; Weiguang Zhao; Clayton Small; Yogendra Kharode; Paul J Yaworsky; Mary L Bouxsein; Padmalatha S Reddy; Peter V N Bodine; John A Robinson; Bheem Bhat; James Marzolf; Robert A Moran; Frederick Bex
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

7.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

Authors:  Ralph Sakkers; Dieke Kok; Raoul Engelbert; Alice van Dongen; Maarten Jansen; Hans Pruijs; Ab Verbout; Dave Schweitzer; Cuno Uiterwaal
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

8.  Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta.

Authors:  G S Barsh; P H Byers
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Synthesis and processing of a type I procollagen containing shortened pro-alpha 1(I) chains by fibroblasts from a patient with osteogenesis imperfecta.

Authors:  C J Williams; D J Prockop
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

10.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.

Authors:  Masaki Kato; Millan S Patel; Regis Levasseur; Ivan Lobov; Benny H-J Chang; Donald A Glass; Christine Hartmann; Lan Li; Tae-Ho Hwang; Cory F Brayton; Richard A Lang; Gerard Karsenty; Lawrence Chan
Journal:  J Cell Biol       Date:  2002-04-15       Impact factor: 10.539

View more
  33 in total

Review 1.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

2.  Activation of Wnt Signaling by Mechanical Loading Is Impaired in the Bone of Old Mice.

Authors:  Nilsson Holguin; Michael D Brodt; Matthew J Silva
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

Review 3.  The genetics of bone mass and susceptibility to bone diseases.

Authors:  David Karasik; Fernando Rivadeneira; Mark L Johnson
Journal:  Nat Rev Rheumatol       Date:  2016-04-07       Impact factor: 20.543

4.  Exome sequencing reveals a novel homozygous splice site variant in the WNT1 gene underlying osteogenesis imperfecta type 3.

Authors:  Muhammad Umair; Bader Alhaddad; Afzal Rafique; Abid Jan; Tobias B Haack; Elisabeth Graf; Asmat Ullah; Farooq Ahmad; Tim M Strom; Thomas Meitinger; Wasim Ahmad
Journal:  Pediatr Res       Date:  2017-07-26       Impact factor: 3.756

5.  The brains of the bones: how osteocytes use WNT1 to control bone formation.

Authors:  Frank Rauch
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

6.  Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis.

Authors:  Kyu Sang Joeng; Yi-Chien Lee; Joohyun Lim; Yuqing Chen; Ming-Ming Jiang; Elda Munivez; Catherine Ambrose; Brendan H Lee
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 7.  Wnt signaling and cellular metabolism in osteoblasts.

Authors:  Courtney M Karner; Fanxin Long
Journal:  Cell Mol Life Sci       Date:  2016-11-26       Impact factor: 9.261

8.  WNT1-associated osteogenesis imperfecta with atrophic frontal lobes and arachnoid cysts.

Authors:  Piranit Nik Kantaputra; Yuddhasert Sirirungruangsarn; Pannee Visrutaratna; Sasitorn Petcharunpaisan; Bruce M Carlson; Worrachet Intachai; Jutamas Sudasna; Jatupol Kampuansai; Prapai Dejkhamron
Journal:  J Hum Genet       Date:  2019-01-28       Impact factor: 3.172

Review 9.  Value of rare low bone mass diseases for osteoporosis genetics.

Authors:  Alice Costantini; Outi Mäkitie
Journal:  Bonekey Rep       Date:  2016-01-06

10.  Wntless spatially regulates bone development through β-catenin-dependent and independent mechanisms.

Authors:  Zhendong A Zhong; Juraj Zahatnansky; John Snider; Emily Van Wieren; Cassandra R Diegel; Bart O Williams
Journal:  Dev Dyn       Date:  2015-08-21       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.